Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. NIV for acute respiratory failure in COPD: high in-hospital mortality is determined by patient selection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Listening to music prior to bronchoscopy reduces anxiety - a randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. ECG with alternating electric axis in relation to left-sided tension pneumothorax: a case report and review of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Feasibility of high-intensity training in asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Neonatal Urine Metabolic Profiling and Development of Childhood Asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Fish-oil supplementation in pregnancy, child metabolomics and asthma risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sensitivity of Multiple Breath Washout to Detect Mild to Moderate Asthma in Adolescence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging. Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma. Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab. Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to -0.94 annual exacerbations (95% CI -1.08;-0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contributed with data on percentage of patients experiencing ≥50% reduction inoral corticosteroid treatment, showing an effect of 20% (95% CI 2.3;47) in favour of anti-IL-5 treatment (mepolizumab), thus exceeding the predefined MCID of 10%. Quality of evidence was considered low. Compared to placebo, anti-IL-5 showed significant improvements in lung function, asthma control, and asthma-related quality of life, but below the MCIDs. No differences were observed for serious adverse events and number of patients, who dropped out. No studies evaluating sickleave or head-to-head comparisons were identified. By indirect comparison, we found no significant difference between mepolizumab and reslizumab in any ofthe predefined clinical outcomes. OCS treatment reduction could not be compared due to lack of reslizumab studies investigating this outcome. Conclusions: Mepolizumab and reslizumab provide significant and clinically relevant improvements in exacerbation rate and OCS reduction. Indirect, inter-study comparisons revealed no differences between the anti-IL-5 drugs in efficacy or safety measures.

OriginalsprogEngelsk
TidsskriftEuropean Clinical Respiratory Journal
Vol/bind5
Udgave nummer1
Sider (fra-til)1536097
ISSN2001-8525
DOI
StatusUdgivet - 2018

ID: 56349227